Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 29, Issue 8, 2014, Pages 1563-1570

  Siwy, Justyna ^a,b   Schanstra, Joost P ^a,c,d   Argiles, Angel ^e,f,g   Bakker, Stephan J L ^h   Beige, Joachim ⁱ   Boucek, Petr ^j   Brand, Korbinian ^k   Delles, Christian ^l   Duranton, Flore ^e   Fernandez Fernandez, Beatriz ^m   Jankowski, Marie Luise ^b   Al Khatib, Mohammad ⁿ   Kunt, Thomas ⁿ   Lajer, Maria ^o   Lichtinghagen, Ralf ^k   Lindhardt, Morten ^o   Maahs, David M ^p   Mischak, Harald ^a,l   Mullen, William ^l   Navis, Gerjan ^h   Noutsou, Marina ^q   Ortiz, Alberto ^m   Persson, Frederik ^o   Petrie, John R ^l   Roob, Johannes M ^r   Rossing, Peter ^o,s,t   Ruggenenti, Piero ^u,v   Rychlik, Ivan ^w   Serra, Andreas L ^x   Snell Bergeon, Janet ^p   Spasovski, Goce ^y   Stojceva Taneva, Olivera ^y   Trillini, Matias ^u   Von Der Leyen, Heiko ^z   Winklhofer Roob, Brigitte M ^aa   Zürbig, Petra ^a   Jankowski, Joachim ^b   more..

^a Mosaiques Diagnostics GmbH Hanover   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSERM   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e RD Nephrologie   (France)

^f Centre de Dialyse Néphrologie Dialyse St Guilhem   (France)

^g Service de Néphrologie Dialyse Péritonéale et Transplantation   (France)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Klinikum St Georg   (Germany)

^j INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m 28400 Madrid   (Spain)

ⁿ Center for Diabetes and Endocrinology   (United Arab Emirates)

^o STENO DIABETES CENTER   (Denmark)

^p UNIVERSITY OF COLORADO DENVER   (United States)

^q UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^r MEDICAL UNIVERSITY OF GRAZ   (Austria)

^s AARHUS UNIVERSITY   (Denmark)

^t UNIVERSITY OF COPENHAGEN   (Denmark)

^u MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^v Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^w CHARLES UNIVERSITY   (Czech Republic)

^x UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^y SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^z Hannover Clinical Trial Center   (Germany)

^aa UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

biomarkers; chronic kidney disease; diabetic nephropathy; diagnosis; urine proteomics

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA1 GLYCOPROTEIN; ANTITHROMBIN III; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; CD99 ANTIGEN; COLLAGEN; COLLAGEN ALPHA1; COLLAGEN ALPHA2; CREATININE; FETUIN A; FIBRINOGEN; PREALBUMIN; SECRETORY COMPONENT; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CAPILLARY ELECTROPHORESIS; CLASSIFIER; COMPUTER PROGRAM; CONTAINER; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PEPTIDOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STORAGE TEMPERATURE; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS; VERY ELDERLY;

BIOMARKERS; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIAGNOSIS; URINE PROTEOMICS;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDOMIMETICS; PROSPECTIVE STUDIES; PROTEOMICS;

EID: 84904970447     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu039     Document Type: Article

References (36)

1. Danaei G, Finucane MM, Lu Y et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40
2. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
3. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: Global dimension and perspectives. Lancet 2013; 382: 260-272
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713
5. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
7. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 462-465
8. Lambers Heerspink HJ, de Zeeuw D. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 458-461
9. Perkins BA, Ficociello LH, Roshan B et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010; 77: 57-64
10. Good DM, Zürbig P, Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9: 2424-2437
11. Roscioni SS, de Zeeuw D, Hellemons ME et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2012; 56: 259-267
12. Zürbig P, Jerums G, Hovind P et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012; 61: 3304-3313
13. Argiles A, Siwy J, Duranton F et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013; 8: E62837
14. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254
15. Theodorescu D, Schiffer E, Bauer HW et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2008; 2: 556-570
16. Jantos-Siwy J, Schiffer E, Brand K et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009; 8: 268-281
17. Wittke S, Mischak H, Walden M et al. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches. Electrophoresis 2005; 26: 1476-1487
18. Haubitz M, Good DM, Woywodt A et al. Identification and validation of urinary biomarkers for differential diagnosis and dvaluation of therapeutic intervention in ANCA associated vasculitis. Mol Cell Proteomics 2009; 8: 2296-2307
19. Neuhoff N, Kaiser T, Wittke S et al. Mass spectrometry for the detection of differentially expressed proteins: A comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 149-156
20. Coon JJ, Zürbig P, Dakna M et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008; 2: 964-973
21. Siwy J, MullenW, Golovko I et al. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 2011; 5: 367-374
22. DeLeo JM, DeLeo JM. Receiver operating characteristic laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty. 318-325. 1993. College Park, MD, USA, Second International Symposium on Uncertainty Modeling and Analysis. 4-25-1993.
23. Mischak H. How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS. Proteomics Clin Appl 2012; 6: 437-442
24. Mischak H, Ioannidis JP, Argiles A et al. Implementation of proteomic biomarkers: Making it work. Eur J Clin Invest 2012; 42: 1027-1036
25. Dakna M, Harris K, Kalousis A et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 2010; 11: 594
26. Mischak H, Allmaier G, Apweiler R et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010; 2: 46ps42
27. Molin L, Seraglia R, Lapolla A et al. A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. J Proteomics 2012; 75: 5888-5897
28. Mischak H, Vlahou A, Ioannidis JP. Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. Clin Biochem 2013; 46: 432-443
29. Argiles A, Mourad G, Mion C et al. Two-dimensional gel electrophoresis of urinary proteins in kidney diseases. Contrib Nephrol 1990; 83: 1-8
30. Candiano G, Musante L, Bruschi M et al. Repetitive fragmentation products of albumin and alpha1-Antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol 2006; 17: 3139-3148
31. Kwak NJ, Heo Y, Jin DC et al. Proteomic analysis of alpha-1-Antitrypsin in immunoglobulin A nephropathy. Proteomics Clin Appl 2007; 1: 420-428
32. Varghese SA, Powell TB, Budisavljevic MN et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007; 18: 913-922
33. Rossing K, Mischak H, Rossing P et al. The urinary proteome in diabetes and diabetes-Associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008; 2: 997-1007
34. Meguid El NA, Bello AK. Chronic kidney disease: The global challenge. Lancet 2005; 365: 331-340
35. Noone D, Licht C. Chronic kidney disease: A new look at pathogenetic mechanisms and treatment options. Pediatr Nephrol 2013; Doi: 10.1007/ s00467-013-2436-5
36. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23: 1917-1928